March 10, 2022
FDA: Fresenius Kabi recalls Sodium Acetate Injection, USP, 400 mEq/100 mL
Editor's Note
The Food and Drug Administration on March 7 posted the recall by Fresenius Kabi USA (Lake Zurich, Illinois) of seven lots of its Sodium Acetate Injection, USP, 400 mEq/100 mL
The recall was initiated because of the presence of particulate matter found in reserve and/or stability sample vials.
The lot (Batch) numbers are: 6124193, 6124196, 6124226, 6124532, 6125333, 6125678, and 6126846. These lots were distributed between September 2020 and November 2021.
To date, no adverse event reports have been received for these recalled lots.
Free Daily News
- Legislation proposes to halt Medicare physician payment cuts
- Cigna ties executive pay to patient experience
- Proposed tax credit aims to bolster nurse preceptor ranks
- Study links financial conflicts of interest to favorable robotic bariatric surgery research
- Hospitals double down on ambulatory care expansion with major investments
- Study: Post-laparotomy incisional negative pressure wound therapy fails to reduce infection risk
- FDA announces multiple Class 1 recalls
- Study: ERAS protocol reduces opioid use after cardiac surgery
- Study: Prehabilitation reduces surgical complications, speeds recovery
- Commentary: Studies show how surgeon decisions follow the money
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement